3rd Circ. Declines To Hear Mylan, Celgene Antitrust Fight

Law360, New York (March 6, 2015, 4:55 PM EST) -- The Third Circuit on Thursday rejected Celgene Corp.'s bid for an immediate review of a New Jersey federal judge's decision not to toss Mylan Pharmaceuticals Inc.'s antitrust suit accusing Celgene of gaming federal drug safety measures to block lower-priced generic versions of its blockbuster cancer drugs Thalomid and Revlimid.

Celgene had sought to launch an immediate challenge of a December ruling by U.S. District Judge Esther Salas that kept most of Mylan's suit alive. Judge Salas had certified Celgene's request for interlocutory appeal in January, but the Third Circuit issued an order Thursday that denied Celgene's petition.

In a separate letter...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!